Axsome Therapeutics (AXSM) Receivables (2022 - 2026)

Axsome Therapeutics' Receivables history runs 5 years deep, the most recent figure standing at $251.1 million for Q1 2026.

• In Q1 2026, Receivables rose 42.5% year-over-year to $251.1 million; the TTM figure through Mar 2026 stood at $251.1 million (up 42.5% YoY), while the FY2025 annual figure was $224.5 million, up 44.35% from the prior year.
• Receivables came in at $251.1 million for Q1 2026 at Axsome Therapeutics, up from $224.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $251.1 million in Q1 2026 to a low of $16.2 million in Q2 2022.
• A 5-year average of $123.1 million and a median of $115.7 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables jumped 413.75% in 2023 and soared 42.5% in 2026, its largest moves.
• Axsome Therapeutics' Receivables stood at $37.7 million in 2022, then soared by 184.68% to $107.3 million in 2023, then soared by 44.9% to $155.5 million in 2024, then jumped by 44.35% to $224.5 million in 2025, then climbed by 11.85% to $251.1 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $251.1 million, $224.5 million, and $196.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison